DE60225899D1 - Ng atopischer dermatitis - Google Patents

Ng atopischer dermatitis

Info

Publication number
DE60225899D1
DE60225899D1 DE60225899T DE60225899T DE60225899D1 DE 60225899 D1 DE60225899 D1 DE 60225899D1 DE 60225899 T DE60225899 T DE 60225899T DE 60225899 T DE60225899 T DE 60225899T DE 60225899 D1 DE60225899 D1 DE 60225899D1
Authority
DE
Germany
Prior art keywords
decoy
stat
atopic dermatitis
decoys
gata
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60225899T
Other languages
English (en)
Other versions
DE60225899T2 (de
Inventor
Ryuichi Morishita
Motokuni Aoki
Toshio Ogihara
Yasufumi Kaneda
Hiroshige Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anges Inc
Original Assignee
Anges MG Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges MG Inc filed Critical Anges MG Inc
Application granted granted Critical
Publication of DE60225899D1 publication Critical patent/DE60225899D1/de
Publication of DE60225899T2 publication Critical patent/DE60225899T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60225899T 2001-02-20 2002-02-06 TOPISCHE ANWENDUNG EINES NF-kB DECOYS ZUR BEHANDLUNG ATOPISCHER DERMATITIS Expired - Lifetime DE60225899T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001044350 2001-02-20
JP2001044350 2001-02-20
PCT/JP2002/000990 WO2002066070A1 (fr) 2001-02-20 2002-02-06 Compositions pharmaceutiques contenant un leurre et procede d'utilisation associe

Publications (2)

Publication Number Publication Date
DE60225899D1 true DE60225899D1 (de) 2008-05-15
DE60225899T2 DE60225899T2 (de) 2009-04-09

Family

ID=18906362

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60225899T Expired - Lifetime DE60225899T2 (de) 2001-02-20 2002-02-06 TOPISCHE ANWENDUNG EINES NF-kB DECOYS ZUR BEHANDLUNG ATOPISCHER DERMATITIS

Country Status (11)

Country Link
US (2) US9012417B2 (de)
EP (2) EP1362600B1 (de)
JP (2) JP3778357B2 (de)
AT (1) ATE390938T1 (de)
CY (1) CY1108165T1 (de)
DE (1) DE60225899T2 (de)
DK (1) DK1362600T3 (de)
ES (1) ES2307733T3 (de)
PT (1) PT1362600E (de)
TW (1) TWI308492B (de)
WO (1) WO2002066070A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE395065T1 (de) * 1993-10-29 2008-05-15 Brigham & Womens Hospital Therapeutische verwendung von cis-element-fallen in vivo
TWI308492B (de) 2001-02-20 2009-04-11 Anges Mg Inc
DE10148886A1 (de) * 2001-10-04 2003-04-30 Avontec Gmbh Inhibition von STAT-1
JP4594233B2 (ja) * 2003-05-09 2010-12-08 竜一 森下 薬液が収容された針無注射器
AU2003252493A1 (en) * 2003-07-09 2005-01-28 Anges Mg, Inc. Pharmaceutical composition containing decoy and method of using the same
CN1842349A (zh) * 2003-08-29 2006-10-04 安琪士摩奇株式会社 使用无针注射器进行皮肤疾病基因治疗
WO2005056020A2 (en) * 2003-12-02 2005-06-23 Corgentech, Inc. Nf-kb oligonucleotide decoy molecules
US8034619B2 (en) 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
JP2008513513A (ja) * 2004-09-21 2008-05-01 アネシヴァ， インコーポレイテッド ポリヌクレオチドの送達
ATE509100T1 (de) 2004-10-22 2011-05-15 Anges Mg Inc Chimäre (doppel-) attrappe
US20090214630A1 (en) * 2005-05-10 2009-08-27 Warren Strober Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
EP1892293A4 (de) * 2005-06-06 2008-12-10 Anges Mg Inc Transkriptionsfaktorköder
EP1915162A4 (de) * 2005-07-27 2009-08-26 Agency Science Tech & Res Modulatoren
EP1978096A1 (de) 2005-12-22 2008-10-08 Genomidea Inc Neues oligonukleotid und dieses umfassender nf-kappa-b-köder
US20090227661A1 (en) * 2005-12-22 2009-09-10 Zhiguo Wang Transcription factor decoy oligodeoxynucleotides having multiple cis elements
JP4602298B2 (ja) * 2006-08-31 2010-12-22 ホソカワミクロン株式会社 医薬製剤
WO2008099906A1 (ja) 2007-02-16 2008-08-21 Anges Mg, Inc. 歯周病、及び外科手術による歯槽骨欠損の治療剤
US20080249044A1 (en) * 2007-04-03 2008-10-09 Masaya Tanaka Nucleic acid external skin formulation
PL2158316T3 (pl) 2007-05-11 2015-10-30 Adynxx Inc Ekspresja genowa oraz ból
KR20100127300A (ko) * 2008-03-28 2010-12-03 안게스 엠지 인코포레이티드 전사 인자 디코이를 유효 성분으로 하는 외용제 조성물
EP3511022A1 (de) 2012-05-10 2019-07-17 Adynxx, Inc. Formulierungen zur abgabe von wirkstoffen
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2361756A (en) * 1942-03-31 1944-10-31 George W Fiero Ointments and the like
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
US4301145A (en) * 1980-07-28 1981-11-17 Cestari Joseph E Antiseptic skin cream
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
JPH05331066A (ja) * 1992-05-25 1993-12-14 Toko Yakuhin Kogyo Kk 尋常性ざ瘡治療用組成物
ATE395065T1 (de) 1993-10-29 2008-05-15 Brigham & Womens Hospital Therapeutische verwendung von cis-element-fallen in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
CA2203566C (en) * 1994-10-24 2001-10-23 Yuko Hosokawa Percutaneously administration preparation
EP0824918B1 (de) * 1995-05-12 2007-03-28 AnGes MG, Inc. HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN
AU708096B2 (en) * 1995-11-21 1999-07-29 Icn Pharmaceuticals, Inc. Inhibition of tumor growth by antisense oligonucleotides for IL-8 and IL-8 receptor
ATE321882T1 (de) * 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
JP2001055331A (ja) 1999-06-11 2001-02-27 Toyama Chem Co Ltd アトピー性皮膚炎治療剤
CN101302536A (zh) * 2000-02-02 2008-11-12 安增子摩祺株式会社 用于基因转移的病毒包膜载体
DE10049549A1 (de) 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
TWI308492B (de) 2001-02-20 2009-04-11 Anges Mg Inc
DE60231063D1 (de) * 2002-02-01 2009-03-19 Anges Mg Inc N zur behandlung von aneurysmen
JP4971609B2 (ja) 2004-08-27 2012-07-11 アンジェスＭｇ株式会社 核酸皮膚外用製剤
JP2006111591A (ja) 2004-10-15 2006-04-27 Anges Mg Inc 核酸医薬を標的特異的に細胞内送達するための製剤

Also Published As

Publication number Publication date
EP1362600A4 (de) 2005-09-21
US20090105183A1 (en) 2009-04-23
ATE390938T1 (de) 2008-04-15
CY1108165T1 (el) 2014-02-12
JP4987022B2 (ja) 2012-07-25
DK1362600T3 (da) 2008-07-28
EP1690544A2 (de) 2006-08-16
EP1690544A3 (de) 2012-03-07
DE60225899T2 (de) 2009-04-09
EP1362600B1 (de) 2008-04-02
EP1362600A1 (de) 2003-11-19
US20040162251A1 (en) 2004-08-19
US9012417B2 (en) 2015-04-21
PT1362600E (pt) 2008-07-09
JPWO2002066070A1 (ja) 2004-06-17
JP2009102428A (ja) 2009-05-14
EP1690544B1 (de) 2017-09-13
JP3778357B2 (ja) 2006-05-24
WO2002066070A1 (fr) 2002-08-29
ES2307733T3 (es) 2008-12-01
TWI308492B (de) 2009-04-11

Similar Documents

Publication Publication Date Title
CY1108165T1 (el) ΤΟΠΙΚΗ ΧΡΗΣΗ ΔΟΛΩΜΑΤΟΣ NF-κΒ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΑΤΟΠΙΚΗΣ ΔΕΡΜΑΤΙΤΙΔΑΣ
WO2002043652A3 (en) Anti-proliferative drugs
WO2001048190A8 (en) Therapeutic uses of lna-modified oligonucleotides
ES2191192T3 (es) Tienopirimidinas.
DE69533551D1 (de) Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
EP1251126A3 (de) Fluor-substituierte benzensulfonyl-derivate zur behandlung von entzündungen
CY1105070T1 (el) Μεθοδος και συνθεσεις που χρησιμοποιουν κιναζολινονες
ES2192839T3 (es) Timosina beta 4 oxidada.
TR200302214T4 (tr) Psoriasis tedavisi için kullanilan pteridine bileşkenleri
HK1056728A1 (en) Ortho-substituted anthranilic acid amides and their use as medicaments
MY138883A (en) Use of asiatic acid for treatment of cencer
WO2003026563A3 (en) Conjugated anti-psychotic drugs and uses thereof
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
ES2178761T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de infe cciones cutaneas.
ZA200703992B (en) 5, 6, 7-Trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use
BR0115882A (pt) Emprego de compostos de 1-fenil-3-dimetilaminopropano no tratamento da incontinência urinária
WO2003103699A8 (en) USE OF RAMOPLANIN TO TREAT DISORDERS ASSOCIATED WITH THE TAKING OF ANTIBIOTICS
WO2005056520A8 (en) Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy
WO2003024996A3 (de) Antibakterielle makrozyklen
EP2250887A3 (de) Verwendung des nicht antibakterielle Tetrazyklin-analog CMT-1002, und Zubereitungen daraus, zur Behandlung von bakteriellen Exotoxinen
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
WO2000063348A3 (fr) Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition